These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 18690865

  • 1. Modulation of fatty acids oxidation in heart failure by selective pharmacological inhibition of 3-ketoacyl coenzyme-A thiolase.
    Fragasso G, Spoladore R, Cuko A, Palloshi A.
    Curr Clin Pharmacol; 2007 Sep; 2(3):190-6. PubMed ID: 18690865
    [Abstract] [Full Text] [Related]

  • 2. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase.
    Lopaschuk GD, Barr R, Thomas PD, Dyck JR.
    Circ Res; 2003 Aug 08; 93(3):e33-7. PubMed ID: 12869392
    [Abstract] [Full Text] [Related]

  • 3. Effects of metabolic approach in diabetic patients with coronary artery disease.
    Fragasso G, Salerno A, Spoladore R, Cera M, Montanaro C, Margonato A.
    Curr Pharm Des; 2009 Aug 08; 15(8):857-62. PubMed ID: 19275650
    [Abstract] [Full Text] [Related]

  • 4. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
    MacInnes A, Fairman DA, Binding P, Rhodes Ja, Wyatt MJ, Phelan A, Haddock PS, Karran EH.
    Circ Res; 2003 Aug 08; 93(3):e26-32. PubMed ID: 12869391
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of free fatty acids metabolism as a therapeutic target in patients with heart failure.
    Fragasso G.
    Int J Clin Pract; 2007 Apr 08; 61(4):603-10. PubMed ID: 17394434
    [Abstract] [Full Text] [Related]

  • 6. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
    Kantor PF, Lucien A, Kozak R, Lopaschuk GD.
    Circ Res; 2000 Mar 17; 86(5):580-8. PubMed ID: 10720420
    [Abstract] [Full Text] [Related]

  • 7. Metabolic therapy of heart failure.
    Fragasso G, Salerno A, Spoladore R, Bassanelli G, Arioli F, Margonato A.
    Curr Pharm Des; 2008 Mar 17; 14(25):2582-91. PubMed ID: 18991675
    [Abstract] [Full Text] [Related]

  • 8. Treatment with the 3-ketoacyl-CoA thiolase inhibitor trimetazidine does not exacerbate whole-body insulin resistance in obese mice.
    Ussher JR, Keung W, Fillmore N, Koves TR, Mori J, Zhang L, Lopaschuk DG, Ilkayeva OR, Wagg CS, Jaswal JS, Muoio DM, Lopaschuk GD.
    J Pharmacol Exp Ther; 2014 Jun 17; 349(3):487-96. PubMed ID: 24700885
    [Abstract] [Full Text] [Related]

  • 9. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation.
    Dyck JR, Cheng JF, Stanley WC, Barr R, Chandler MP, Brown S, Wallace D, Arrhenius T, Harmon C, Yang G, Nadzan AM, Lopaschuk GD.
    Circ Res; 2004 May 14; 94(9):e78-84. PubMed ID: 15105298
    [Abstract] [Full Text] [Related]

  • 10. [Metabolic therapy for heart failure].
    Loiacono F, Alberti L, Lauretta L, Puccetti P, Silipigni C, Margonato A, Fragasso G.
    Recenti Prog Med; 2014 May 14; 105(7-8):288-94. PubMed ID: 25072544
    [Abstract] [Full Text] [Related]

  • 11. [Ischemic heart disease and left ventricular dysfunction: the role of trimetazidine].
    Belardinelli R.
    Ital Heart J; 2004 Mar 14; 5 Suppl 2():23S-28S. PubMed ID: 15074774
    [Abstract] [Full Text] [Related]

  • 12. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated?
    Lopaschuk GD.
    Coron Artery Dis; 2001 Feb 14; 12 Suppl 1():S8-11. PubMed ID: 11286307
    [Abstract] [Full Text] [Related]

  • 13. The effects of chronic trimetazidine treatment on mechanical function and fatty acid oxidation in diabetic rat hearts.
    Onay-Besikci A, Guner S, Arioglu E, Ozakca I, Ozcelikay AT, Altan VM.
    Can J Physiol Pharmacol; 2007 May 14; 85(5):527-35. PubMed ID: 17632588
    [Abstract] [Full Text] [Related]

  • 14. Metabolic support for the heart: complementary therapy for heart failure?
    Heggermont WA, Papageorgiou AP, Heymans S, van Bilsen M.
    Eur J Heart Fail; 2016 Dec 14; 18(12):1420-1429. PubMed ID: 27813339
    [Abstract] [Full Text] [Related]

  • 15. The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway.
    Liu Z, Chen JM, Huang H, Kuznicki M, Zheng S, Sun W, Quan N, Wang L, Yang H, Guo HM, Li J, Zhuang J, Zhu P.
    Metabolism; 2016 Mar 14; 65(3):122-30. PubMed ID: 26892523
    [Abstract] [Full Text] [Related]

  • 16. New directions in the treatment of heart failure: targeting free fatty acid oxidation.
    Fragasso G, Spoladore R, Bassanelli G, Cuko A, Montano C, Salerno A, Margonato A.
    Curr Heart Fail Rep; 2007 Dec 14; 4(4):236-242. PubMed ID: 18221621
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. 4-Bromo-2-octenoic acid specifically inactivates 3-ketoacyl-CoA thiolase and thereby fatty acid oxidation in rat liver mitochondria.
    Li JX, Schulz H.
    Biochemistry; 1988 Aug 09; 27(16):5995-6000. PubMed ID: 3191104
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Metabolism of 4-pentenoic acid and inhibition of thiolase by metabolites of 4-pentenoic acid.
    Schulz H.
    Biochemistry; 1983 Apr 12; 22(8):1827-32. PubMed ID: 6133549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.